Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2014Thrombosis and Haemostasis

New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with atrial fibrillation

Comparison

New oral anticoagulants vs Warfarin

Design

Review

Authors

JPJeremy S. PaikinJHJack HirshMLMandy N. Lauw

Discussion

Loading...

Member takes

Overview

Supports NOAC use versus warfarin in AF; leaves open how trial design differences affect interpretation.

Structured PICO

P
Population
Patients with atrial fibrillation
I
Intervention
New oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban)
C
Comparator
Warfarin
O
Outcome
Stroke prevention

This review highlights how differences in study design, analysis plans, and unexpected events across the four major NOAC trials impact the interpretation of their results and subsequent clinical practice.

Cite This Study

Paikin et al. (2014) studied this question.

synapsesocial.com/papers/6a737d24007d73ca2ffb6605https://doi.org/10.1160/th13-11-0918
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New oral anticoagulant agents – general features and outcomes in subsets of patients2014 · 64 citations
  2. 2A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin2013 · 15 citations
  3. 3Novel anticoagulants in atrial fibrillation stroke prevention2012 · 19 citations
  4. 4Novel Oral Anticoagulants: A Review of New Agents2013 · 21 citations
  5. 5THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE2016 · 4 citations